Anabolic Lab

Analytical Lab Testing for Anabolic Steroid Harm Reduction

https://anaboliclab.com

Lab Report – September 15, 2017

Pharmacom Labs PHARMA Test P100 (100 mg/mL) Testosterone Propionate



If you like the attached report, please visit <u>our website</u> to find out how you can support independent and objective lab testing.



Simec AG

Gärtnereiweg 4 B CH-4665 Oftringen Telefon +41 62 752 83 08 Fax +41 62 752 83 09 E-Mail info@simec.ch www.simec.ch

Test report Number

Object of analysis:

Pharma Test P100

Customer:

AnabolicLab.com

Samples: 1

Batch:

PHTE00002PV

Receipt: 14.08.2017

C 60240

Subject:

Content, Identification Testosterone propionate

Method(s):

HPLC, SOP M 006

Sample / Analysis:	Method	Status	Result	Specification	complies
Testosterone propionate:					
Identification Content	HPLC HPLC	N N	complies 102 mg/mL	complies 100 mg/mL	yes -
TAMC TYMC	SOP M 006 SOP M 006		< 1 KBE/mL < 1 KBE/mL	-	- :

Method-status:

G = GMP A = accreditated V = generally validated P = validated on product N = not validated

E = external lab

Remarks:

The sample(s) mentioned above have been analysed as they have been sent to us by the client. We have not controlled external processes like manufacturing, labelling, sampling, shipping, storage. These results are for information only and do not compensate for correct quality control by the manufacturer/distributor. Generally, pharmaceutical products have to be produced and distributed under full GMP/GDP regime, including GMP-compliant analyses with validated methods. It is not allowed to use this analysis in the context of doping/sports/competitions or any other illegal action, neither by the athlete nor by the tutor/trainer or any other person.

Signatures:

controlled & released:

Staff:

completed:

15.09.2017

page 1 of 1

The enclosed results refer exclusively to the object of examination described above. The measuring accuracy is available on request. Only handwritten signatures are valid. Without written permission, it is not allowed to publish single parts of this report.